FOLH1 and neuroendocrine neoplasm: For quantification of 177Lu, however, the most obvious application would be for the use in dosimetry for radionuclide therapies with ligands such as 177Lu-PSMA for prostate cancer or 177Lu-DOTATATE/DOTATOC for neuroendocrine tumors.